10-Apr-2026
PRNewswire (Wed, 8-Apr 8:30 AM ET)
PRNewswire (Thu, 2-Apr 8:30 AM ET)
PRNewswire (Tue, 31-Mar 6:00 PM ET)
PRNewswire (Thu, 26-Mar 8:30 AM ET)
PRNewswire (Wed, 25-Mar 8:30 AM ET)
PRNewswire (Tue, 24-Mar 8:30 AM ET)
PRNewswire (Fri, 20-Mar 8:30 AM ET)
PRNewswire (Mon, 16-Mar 8:30 AM ET)
Caris Life Sciences to Showcase Five Studies at the 2026 USCAP Annual Meeting
PRNewswire (Wed, 11-Mar 8:30 AM ET)
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
Caris Life Sciences trades on the NASDAQ stock market under the symbol CAI.
As of April 10, 2026, CAI stock price declined to $18.05 with 2,467,865 million shares trading.
CAI has a beta of 1.79, meaning it tends to be more sensitive to market movements. CAI has a correlation of 0.16 to the broad based SPY ETF.
CAI has a market cap of $5.09 billion. This is considered a Mid Cap stock.
Last quarter Caris Life Sciences reported $293 million in Revenue and $.28 earnings per share. This beat revenue expectation by $12 million and exceeded earnings estimates by $.21.
The top ETF exchange traded funds that CAI belongs to (by Net Assets): IBB, IWR, IWP, IDNA, IWF.
CAI support price is $18.44 and resistance is $19.97 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CAI shares will trade within this expected range on the day.
